Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
REDWOOD CITY, Calif., May 03, 2018 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 9585106 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 9585106 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
